Evidence map›Paper›PMID 37027203›Full record

ArticleJMIR public health and surveillance2023

Health Care-Seeking Behaviors, Disease Progression, Medications, Knowledge of, and Attitudes Toward Systemic Lupus Erythematosus in China: Cross-sectional Survey Study.

Zonglin Dai, Xinxiang Huang, Fei Yuan, Tianwang Li, Baozhao Xie, He Lin, Pingting Yang, Xueyi Li, Shuiming Xu, Jinjun Zhao and 12 more

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 20 institutions in 2 countries.

Zonglin DaiSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.ORCID 0000-0003-0272-3248
Xinxiang HuangDepartment of Rheumatology and Immunology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.ORCID 0000-0002-9154-5801
Fei YuanDepartment of Rheumatology, Dongguan People's Hospital, Dongguan, China.ORCID 0009-0001-6975-9969
Tianwang LiDepartment of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China.ORCID 0000-0001-6438-2691
Baozhao XieDepartment of Rheumatology and Immunology, The Seventh Affiliated Hospital, Guangxi Medical University, Wuzhou, China.ORCID 0009-0007-8358-4783
He LinDepartment of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian, China.ORCID 0000-0001-8030-8280
Pingting YangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, Shenyang, China.ORCID 0000-0002-2800-7947
Xueyi LiDepartment of Rheumatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0009-0005-9727-7085
Shuiming XuDepartment of Rheumatology and Immunology, Ganzhou Municipal Hospital, Ganzhou, China.ORCID 0009-0006-9101-1099
Jinjun ZhaoDepartment of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0002-2664-1389
Yukai WangDivision of Rheumatology, Shantou Central Hospital, Shantou, China.ORCID 0000-0003-2468-3208
Xiang PengDepartment of Rheumatology and Immunology, The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital), Qingyuan, China.ORCID 0009-0006-1574-9016
Simin WeiDivision of Rheumatology, Guigang People's Hospital, Guigang, China.ORCID 0009-0002-9975-6619
Wei HuangDepartment of Rheumatology and Immunology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.ORCID 0009-0008-9730-7872
Jingyang LiDivision of Rheumatology, The Affiliated Zhuzhou Hospital of Xiangya Medical College of Central South University, Zhuzhou, China.ORCID 0009-0003-0662-0091
Jing LiangDepartment of Rheumatology, Huadu Affiliated Hospital of Southern Medical University, Guangzhou, China.ORCID 0009-0004-6068-9732
Xiuhua LiuDivision of Rheumatology, Liuzhou Worker's Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China.ORCID 0000-0002-5511-8204
Yongliang ChuDivision of Rheumatology, Guangdong Province Hospital of Traditional Chinese Medicine, Zhuhai Branch, Zhuhai, China.ORCID 0000-0003-1689-8006
Zhiming ZhangDivision of Rheumatology, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China.ORCID 0009-0004-7500-9007
Renpeng ZhangDivision of Rheumatology, The First People's Hospital of Zhaotong, Zhaotong, China.ORCID 0000-0002-7201-3551
Eric H Y Lau *School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.ORCID 0000-0002-6688-9637
Zhiming Lin *Department of Rheumatology and Immunology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-9341-4303
University of Hong Kong · HKCentral South University · CNDongguan People’s Hospital · CNFirst Hospital of China Medical University · CNFourth Affiliated Hospital of Guangxi Medical University · CNFujian Medical University · CNFujian University of Traditional Chinese Medicine · CNGanzhou People's Hospital · CNGuangdong Provincial People's Hospital · CNGuangxi Medical University · CNGuigang City People's Hospital · CNHainan General Hospital · CNNanfang Hospital · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNShantou Central Hospital · CNSouthern Medical University · CNSun Yat-sen University · CNThe First People's Hospital of Zhaoqing · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs throughout the body. The health care-seeking behaviors, disease progression of SLE, and patients' knowledge of and attitudes toward SLE have not been characterized in China.

objectiveThe aim of this study was to depict the health care-seeking behaviors, disease progression, and medications in patients with SLE and to examine the factors associated with their disease flares, knowledge, and attitudes toward SLE in China.

methodsWe conducted a cross-sectional survey in 27 provinces in China. Descriptive statistical methods were used to depict the demographic characteristics, health care-seeking behaviors, medications, and health status. Multivariable logistic regression models were used to identify the factors associated with disease flares, medication changes, and attitudes toward SLE. An ordinal regression model was used to examine the factors associated with the knowledge of the treatment guidelines.

resultsWe recruited 1509 patients with SLE, and 715 had lupus nephritis (LN). Approximately 39.96% (603/1509) of the patients with SLE were primarily diagnosed with LN, and 12.4% (112/906) developed LN (mean time 5.2 years) from non-LN. Patients whose registered permanent residences or workplaces in other cities from the same province and adjacent provinces seeking health care accounted for 66.9% (569/850) and 48.8% (479/981) of the patients with SLE in the provincial capital cities, respectively. Mycophenolate mofetil was the most commonly used immunosuppressive drug in patients without LN (185/794, 23.3%) and patients with LN (307/715, 42.9%). Femoral head necrosis (71/228, 31.1%) and hypertension (99/229, 43.2%) were the most common adverse event (AE) and chronic disease during treatment, respectively. Change of hospitals for medical consultation (odds ratio [OR] 1.90, 95% CI 1.24-2.90) and development of 1 chronic disease (OR 3.60, 95% CI 2.04-6.24) and AE (OR 2.06, 95% CI 1.46-2.92) and more were associated with disease flares. A pregnancy plan (OR 1.58, 95% CI 1.18-2.13) was associated with changes in medication. Only 242 (16.03%) patients with SLE were familiar with the treatment guidelines, and patients with LN tended to be more familiar with the disease (OR 2.20, 95% CI 1.81-2.68). After receiving treatment, 891 (59.04%) patients changed their attitudes toward SLE from fear to acceptance, and patients with college education or higher (OR 2.09, 95% CI 1.10-4.04) were associated with a positive attitude toward SLE.

conclusionsA large proportion of patients seeking health care in the provincial capital cities of China migrated from other cities. Persistent monitoring of potential AEs and chronic diseases during SLE treatment and managing patients who changed hospitals for medical consultation are essential for controlling disease flares. Patients had insufficient knowledge about SLE treatment guidelines and would benefit from health education to maintain a positive attitude toward SLE.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisCross-Sectional StudiesDelivery of Health CareDisease ProgressionFemaleHumansPregnancyattitudesdisease progressionhealth care–seeking behaviorsknowledgemedicationssystemic lupus erythematosus

Identifiers

PMID37027203
PMCPMC10131714
OpenAlexW4322710923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.